Attentie

Het forum is in alleen-lezen modus.

×
Inhoud voormalig Psorinovo Forum (01 aug 2018)

Het complete forum van de Vereniging Psorinovo is hier terug te vinden (2011-2018). Er kan hier niet meer op de postings gereageerd worden. Als je toch iets zou willen zeggen, plaats dan een nieuw bericht in het nieuwe psoriasispatientennederland.nl/forumc met een link naar het bericht in dit oude forum.

× Ervaringen met het product Psorinovo.

Ervaringen zonder psorinovo maar met DMF

  • Jim
  • Jim's Profielfoto Onderwerp Auteur
  • Offline
  • Administrator
  • Administrator
Meer
4 jaren 3 maanden geleden #1652 door Jim
Jim heeft een nieuw onderwerp gemaakt: Ervaringen zonder psorinovo maar met DMF
Quote:
Background:
Fumaric acid esters (FAEs) have been used for over 30 years in the management of psoriasis.

Objectives:
To determine drug survival of FAEs in patients with psoriasis, treatment-limiting adverse drug events and the range of effective drug doses.

Methods:
A retrospective, single-centre study assessing all patients commenced on FAEs between October 2003 and July 2012. Demographic data, length of treatment, reasons for discontinuation of FAEs, side-effects and range of doses were recorded.

Results:
Two hundred and forty-nine patients [160 (64%) male] were included. The mean age at which FAEs were commenced was 44·5 years (range 17–82 years). The mean length of treatment was 28 months (range 1 week to 106 months). In patients who were commenced on FAEs ≥ 4 years before inclusion in this study, the 4-year drug survival was 60% (64/107). FAEs were discontinued in 146/249 patients (59%); this was due to lack of efficacy in 59/146 (40%) and gastrointestinal upset in 39/146 (27%). A very low dose of FAEs (< 240 mg daily) was successful in maintaining control of psoriasis in 26 (10%) patients. The mean treatment duration of these patients was 64 months (range 32–106 months).

Conclusions:
Fumaric acid esters have a 4-year drug survival rate of 60%, which compares favourably with reported 4-year survival rates of 40% for etanercept and adalimumab and 70% for infliximab. Longer drug survival is more likely in the significant subgroup of patients in whom a very low dose of FAEs is sufficient to control disease. The reasons for this are unclear.

GPG/PGP Fingerprint: A306 E7D0 C1B7 A09B 78A3 E8B3 E44F 88EE A502 9544